Items in basket: 0 Total £0.00
44(0)191 495 8210
Product Catalogue
Product, Code or Supplier:

Request Your Free ZipScript ™ Sample

ZipScript is a new
One-Step RT-qPCR mix
from Enzymatics Inc.

SGS - inspection, verification, testing; certifica
British Society for Immunology
British Society for Histocompatibility & Immunogen
 
Customer Tools
Register Login
Asuragen Launches QuantideX® NGS RNA Lung Cancer Kit

 

Introducing A Highly Sensitive Targeted RNA Sequencing Panel for the Analysis of Gene Fusions and Expression Markers in Non-Small Cell Lung Cancer.

 

 

The QuantideX® NGS RNA Lung Cancer Kit  is a next generation sequencing panel that simultaneously interrogates known clinically-relevant gene fusions, 3’/5’ imbalance markers, exon skipping events, and mRNA expression levels in non-small cell lung cancer (NSCLC) samples.

 

The QuantideX® RNA Lung Cancer Kit is a cGMP manufactured, end-to-end NGS-in-a-Box™ product solution.  The kit is part of an integrated workflow that delivers sequencing-ready libraries in approximately half the time of comparable competitor methods and incorporates push-button analytics that standardize results. Asuragen’s proprietary Sample-Aware™ bioinformatics software solution minimizes the subjective results commonly associated with less integrated product offerings currently on market.

 

The Asuragen QuantideX® NGS RNA Lung Cancer Kit is optimized for use with low-quality and quantity samples such as FFPE and fine-needle aspirations. The highly sensitive assay detects fusions and splice variants at 5% and 1% cell fractions, respectively.

 

“With the release of this new RNA-Seq assay, Asuragen is providing the most comprehensive and sensitive research tool for examining  >100 clinically-relevant NSCLC gene rearrangements across 11 different fusion partners,” commented Matthew McManus, M.D., Ph.D., President and Chief Executive Officer, Asuragen Inc. “In providing an integrated and comprehensive workflow solution, Asuragen’s NGS assays reduce the barrier-to-entry for laboratories considering targeted NGS oncology assays while also providing new options for laboratories already familiar with NGS technology.”

 

 

Please click the following link for further product information QuantideX® NGS RNA Lung Cancer Kit

 
Latest News
Asuragen Expands AmplideX® Portfolio into Alzheimer's & Cognitive Impairment Space with TOMM40 Kit >>
New from ExScale™ Biospecimen Solutions >>
Asuragen Launches QuantideX® NGS RNA Lung Cancer Kit >>
Shipping charges as of 1st January 2017
Fragile X Testing >>
BCR-ABL Monitoring >>
VH Bio on the road >>
Sign up to our newsletter

Call us: 0191 495 8210

email: info@vhbio.com

Find us on Twitter: @VHBio

 

VH Bio Limited.
Registered in England & Wales, Number 2582192.
Registered Office: Unit 11B Station Approach, Team Valley Trading Estate, Gateshead, NE11 0ZF
Tel: +44 (0)191 495 8210 Fax: +44 (0)191 487 4285

Any queries? Please complete the form below:

Name*
Phone
Email*
Message*